Lunai Bioworks Inc. - Common Stock (LNAI)

Oncotelic Therapeutics (OTCQB: OTLC) was featured in BioMedWire editorial coverage examining the growing urgency around effective central nervous system drug delivery, with the company highlighted for its proprietary intranasal nose-to-brain delivery platform designed to bypass the blood-brain barrier and deliver therapeutics directly to the brain. The editorial points to rising global Alzheimer’s cases and increased biodefense focus as major catalysts driving demand for faster, more targeted CNS delivery technologies, positioning Oncotelic’s platform-based approach as part of a broader shift toward delivery innovation as a critical determinant of therapeutic success.

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (BBB), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine's most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) are responding to this challenge with next-generation delivery platforms engineered to circumvent biological barriers and ensure direct, targeted access to the central nervous system (CNS). Oncotelic has developed a proprietary intranasal nose-to-brain (N2B) system capable of rapidly shuttling therapeutics to the brain, a signal of growing industry consensus that delivery innovation, not merely drug discovery, will drive the next wave of breakthroughs in CNS medicine. Oncotelic joins a group of leading biopharma companies working in the biopharmaceutical and advanced therapeutics space, including Amgen Inc. (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV) and Lunai Bioworks Inc. (NASDAQ: LNAI).

Lunai Bioworks (NASDAQ: LNAI) is the plaintiff in a federal securities fraud lawsuit filed in Delaware by national law firms Dickinson Wright and Fox Rothschild, alleging that unidentified “naked” short sellers engaged in a coordinated scheme to manipulate trading in the company’s common stock. The complaint alleges repeated violations of SEC Regulation SHO, including failures to deliver shares reaching as high as 234.6 times the maximum baseline daily rate and periods in which failures to deliver allegedly represented 81.6% of the company’s total outstanding shares.

Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.

A new wave of activity across biotech innovation, artificial intelligence, digital infrastructure, and global manufacturing is drawing increased investor attention as several emerging growth companies report significant developments that could shape their next phase of expansion.

Lunai Bioworks (Nasdaq: LNAI ) is an AI-enabled biotechnology company advancing rapid in vivo phenotypic drug discovery across CNS and biodefense applications. By integrating high-throughput vertebrate screening with machine learning analytics, LNAI seeks to accelerate therapeutic discovery while reducing cost, time, and capital intensity.

Full Alliance Group (OTCQB: FAGI) continues executing its multi-vertical growth strategy as its subsidiary Aquaox Pure Solutions, LLC reports accelerating marketplace traction for JusSpray™, the company’s flagship hypochlorous acid (HOCl) skin defense spray.

Despite the LNAI stock soaring on Tuesday, the company’s shares are still down more than 93% from the stock’s 52-week high of $7.7.